CIPLA vs KREBSBIO: Stock Comparison

Cipla Ltd vs Krebs Biochemicals and Industries Limited

Live data: 22 July 2026, 2:37 PM IST • Source: NSE and company filings

Cipla Ltd is the larger company by market capitalisation. Cipla Ltd shows a higher dividend yield, a higher ROCE and a higher net margin, while Krebs Biochemicals and Industries Limited shows a lower P/E and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Cipla Ltd and Krebs Biochemicals and Industries Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, CIPLA is more favourable on 5 of 11 scored metrics and KREBSBIO on 6These counts are context-free and are not an overall rating.

Key Differences

Market Cap
CIPLA is the larger company
₹1.14 L Cr vs ₹117 Cr
P/E Ratio
KREBSBIO has a lower P/E
0x vs 29.83x
P/B Ratio
KREBSBIO has a lower P/B
0x vs 3.36x
EPS
CIPLA has higher earnings per share
₹48.01 vs ₹-7.85
Dividend Yield
CIPLA has a higher dividend yield
0.9% vs 0%
Revenue Growth (TTM YoY)
KREBSBIO has faster revenue growth
11.6% vs -2.1%
EPS Growth (TTM YoY)
KREBSBIO has faster EPS growth
0% vs -54.6%
Qtr Sales Growth
KREBSBIO has stronger quarterly sales growth
11.6% vs -2.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCIPLAKREBSBIO
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricCIPLAKREBSBIO
Live Price₹1,411.4₹53.41
Day Change-1.47%-3.03%
Volume12.91 L1,997
52-Week High₹1,673₹82.49
52-Week Low₹1,165.7₹38.33
Distance from 52W High-15.64%-35.25%

Valuation

MetricCIPLAKREBSBIO
Market Cap₹1.14 L Cr₹117 Cr
P/E Ratio29.83x0x
P/B Ratio3.36x0x
EPS₹48.01₹-7.85
Book Value₹426.25₹-75.5
Dividend Yield0.9%0%

Growth

MetricCIPLAKREBSBIO
Revenue Growth (TTM YoY)-2.1%11.6%
EPS Growth (TTM YoY)-54.6%0%
Qtr Sales Growth-2.8%11.6%
Qtr Profit Growth-54.6%71.7%

Profitability & Leverage

MetricCIPLAKREBSBIO
ROE11.6%
ROCE15.5%-15.4%
Net Margin13.96%-71.35%
Operating Margin20.9%-23%
Debt to Equity0.02x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricCIPLAKREBSBIO
Promoter Holding9.17%72.74%
FII Holding22.56% 1.37 pp0.5%
DII Holding31.97% 1.25 pp0%
Public Holding16.25% 0.12 pp26.76%

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Cipla Ltd and Krebs Biochemicals and Industries Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.